Tuesday, October 21, 2014

Tuesday Features

Stellar Biotechnologies harvests mollusks for KLH protein

Stellar Biotechnologies harvests mollusks for KLH protein

A mollusk living in the coastal waters off California from Monterey to the Baja Peninsula may hold the key to new therapies to treat cancer and autoimmune diseases. Frank Oakes Stellar Biotechnologies (OTCQB:SBOTF; TSX-V:KLH) has pioneered technology to grow the mollusk, known as the Giant Keyhole Limpet, and produce and purify KLH, or keyhole limpet... [Read more of this feature]


In conversation with Ron Babecoff

In conversation with Ron Babecoff

Ron Babecoff As a co-founder of BiondVax Pharmaceuticals (TASE:BNDX), Ron Babecoff has led the Israeli developer of a universal flu vaccine since its inception in 2003. Prior to BiondVax, Dr. Babecoff was with Omrix Biopharmaceuticals as marketing manager, where he was involved in identifying West Nile Fever treatments and building cooperation with... [Read more of this feature]


How Itamar Medical’s PAT signal is improving health

How Itamar Medical’s PAT signal is improving health

Using an unique and innovative technology known as peripheral arterial tone (PAT), Itamar Medical (TASE:ITMR) is detecting the functioning and health of arteries through a finger sensor for the diagnosis of sleep apnea and heart disease. Gilad Glick “Our technology is a non-invasive measurement of changes in a patient’s pulsatile arterial volume... [Read more of this feature]


More Posts From Tuesday Features

Briefs

Rosetta Genomics in pact for thyroid cancer diagnostic

Rosetta Genomics in pact for thyroid cancer diagnostic

Rosetta Genomics (NASDAQ:ROSG) has initiated a new public-private translational research project with the Institute of Molecular Translational Medicine (IMTM) at Palacky University, Olomouc, Czech Republic. The new partnership will work towards the validation and development of a new thyroid cancer diagnostic tool. The partnership was facilitated by... [Read more of this brief]


HCW starts Oncothyreon at buy

HCW starts Oncothyreon at buy

H.C. Wainwright has launched coverage of Oncothyreon (NASADQ:ONTY) with a “buy” rating and 12-month target price of $4, based on a risk-adjusted revenue and EPS multiples valuation methodology. The stock finished at $1.73 on Monday. “Oncothyreon’s biotechnology franchise is comprised of diverse set of therapeutics, including ONT-380, a potent... [Read more of this brief]


Stifel starts Vitae Pharma at buy

Stifel starts Vitae Pharma at buy

Stifel has initiated coverage of Vitae Pharmaceuticals (NASDAQ:VTAE) with a “buy” rating and price target of $14. The stock closed at $6.30 on Friday. “Vitae’s unique technology platform encompasses the unique ability to rationally design clinical candidates and represents the principal competitive advantage of the company,” writes analyst... [Read more of this brief]


Nuvo Research sells U.S. Pennsaid 2% rights to Horizon


Nuvo Research sells U.S. Pennsaid 2% rights to Horizon


Nuvo Research (TSX:NRI) has sold the U.S. sales and marketing rights of its Pennsaid 2% topical pain reliever to Horizon Pharma (NASDAQ:HZNP) for a cash payment of $45-million. Effective Jan. 1, 2015, Horizon will assume U.S. commercialization of Pennsaid 2% from Nuvo’s former U.S. marketing licensee. Nuvo retains all rights to Pennsaid and Pennsaid... [Read more of this brief]


Novadaq signs India distribution deal with Kirloskar

Novadaq signs India distribution deal with Kirloskar

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has appointed Kirloskar Technologies as the exclusive distributor for its family of fluorescence imaging technologies in India. The relationship between the two companies officially kicked off today with a signing ceremony overseen by the Honourable Ed Fast, Canada’s Minister of International Trade, at... [Read more of this brief]


More Posts From Briefs
Email Newsletters with Constant Contact
Google+